06-01-2026, 07:14 AM
Driven by rise in demand for safe and effective medicines, along with increase in rare and chronic disorders, the plasma fractionation market is evolving steadily
Plasma fractionation is a process employed to purify and separate plasma into individual protein components. These fractionates are then purified, which can further be used as therapeutic medicines, known as plasma-derived therapies or plasma-derived medicinal products. This involves a sequence of processes, including precipitation / chromatography, purification, and virus-inactivation. Plasma fractionation is a highly developed bioprocess that can be carried out from small scale to commercial scale production. It is worth highlighting that more than 30 unique therapeutic plasma proteins have already been developed through plasma fractionation which helps to treat various indications.
The global plasma fractionation market size is $ 5.3 billion in 2025, is projected to reach $ 5.8 billion in 2026 and $ 12.7 billion by 2035, representing a higher CAGR of 9.1% during the forecast period 2026 to 2035.
Plasma-derived therapies have lowered the healthcare expenditures that are incurred during hospitalization and have contributed to socio-economic gains. Hence, they are being increasingly adopted for treatment of a myriad of disease indications. The list of plasma-derived products along with the information on therapeutic applications have been mentioned below:
Most of the plasma fractionation facilities are located in Europe (97%). This is followed by plasma fractionation facilities located in Asia-Pacific (94%) and North America (46%). It is worth highlighting that Aegros (Israel), Grifols (Egypt) and Kamada (Israel) have plasma fractionation facilities located in the rest of the world.
97% of the plasma is fractionated to produce immunoglobulins, this is followed by albumins (94%) and coagulation factors (86%). It is worth highlighting that 30 firms are involved in fractionating blood plasma for the development of all of these aforementioned plasma-derived therapeutic products; examples of such plasma fractionation companies include (in alphabetical order, no specific selection criteria) China National Biotec Group (CNBG), Intas Pharmaceuticals, Merck KGaA, and Oryx Bio-Tech.
Majority (74%) of the plasma fractionators are large companies. This can be attributed to their extensive plasma fractionation facilities and their ability to establish a strong presence in multiple key locations, enabling them to effectively meet the growing demand. Notable examples of such plasma fractionation companies include (in alphabetical order, no specific selection criteria) ADMA Biologics, Biotest, GC Biopharma, and Hualan Biological. Additionally, we came across 6% small players with less than 50 employees; namely (in alphabetical order) CAF-DCF and Evolve Biologics.
To view more details on this report, click on the link
https://www.rootsanalysis.com/reports/plasma-fractionation-market.html
Plasma fractionation is a process employed to purify and separate plasma into individual protein components. These fractionates are then purified, which can further be used as therapeutic medicines, known as plasma-derived therapies or plasma-derived medicinal products. This involves a sequence of processes, including precipitation / chromatography, purification, and virus-inactivation. Plasma fractionation is a highly developed bioprocess that can be carried out from small scale to commercial scale production. It is worth highlighting that more than 30 unique therapeutic plasma proteins have already been developed through plasma fractionation which helps to treat various indications.
The global plasma fractionation market size is $ 5.3 billion in 2025, is projected to reach $ 5.8 billion in 2026 and $ 12.7 billion by 2035, representing a higher CAGR of 9.1% during the forecast period 2026 to 2035.
Plasma-derived therapies have lowered the healthcare expenditures that are incurred during hospitalization and have contributed to socio-economic gains. Hence, they are being increasingly adopted for treatment of a myriad of disease indications. The list of plasma-derived products along with the information on therapeutic applications have been mentioned below:
§ Albumin: Acute Respiratory Distress Syndrome, Burns, Cardiopulmonary Bypass, Hemodialysis, Hypoalbuminemia, Hypovolemia (shock), Surgery and Trauma
§ Alpha-1 Proteinase Inhibitor Therapies: Alpha-1 Antitrypsin Deficiency
§ C1 Esterase Inhibitor Therapies: Hereditary Angioedema
§ Coagulation Factors: Hemophilia A, Hemophilia B, Von Willebrand Disease and Antithrombin III Deficiency
§ Immunoglobulins: Primary Immunodeficiency Disease (PID), Chronic Inflammatory Demyelinating Polyneuropathy (CIDP), Idiopathic Thrombocytpenic Purpura (ITP) and Kawasaki Disease.
During our research, we identified more than 35 players that are engaged in blood plasma fractionation.Most of the plasma fractionation facilities are located in Europe (97%). This is followed by plasma fractionation facilities located in Asia-Pacific (94%) and North America (46%). It is worth highlighting that Aegros (Israel), Grifols (Egypt) and Kamada (Israel) have plasma fractionation facilities located in the rest of the world.
97% of the plasma is fractionated to produce immunoglobulins, this is followed by albumins (94%) and coagulation factors (86%). It is worth highlighting that 30 firms are involved in fractionating blood plasma for the development of all of these aforementioned plasma-derived therapeutic products; examples of such plasma fractionation companies include (in alphabetical order, no specific selection criteria) China National Biotec Group (CNBG), Intas Pharmaceuticals, Merck KGaA, and Oryx Bio-Tech.
Majority (74%) of the plasma fractionators are large companies. This can be attributed to their extensive plasma fractionation facilities and their ability to establish a strong presence in multiple key locations, enabling them to effectively meet the growing demand. Notable examples of such plasma fractionation companies include (in alphabetical order, no specific selection criteria) ADMA Biologics, Biotest, GC Biopharma, and Hualan Biological. Additionally, we came across 6% small players with less than 50 employees; namely (in alphabetical order) CAF-DCF and Evolve Biologics.
https://www.rootsanalysis.com/reports/plasma-fractionation-market.html